110 related articles for article (PubMed ID: 18321361)
1. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas.
Näyhä V; Stenbäck F
APMIS; 2008 Feb; 116(2):107-17. PubMed ID: 18321361
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements.
Emoto M; Iwasaki H; Ishiguro M; Kikuchi M; Horiuchi S; Saito T; Tsukamoto N; Kawarabayashi T
Hum Pathol; 1999 Oct; 30(10):1232-41. PubMed ID: 10534173
[TBL] [Abstract][Full Text] [Related]
3. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Secord AA; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A;
Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma.
Nishida N; Yano H; Komai K; Nishida T; Kamura T; Kojiro M
Cancer; 2004 Sep; 101(6):1364-74. PubMed ID: 15368324
[TBL] [Abstract][Full Text] [Related]
6. Markers of apoptosis and angiogenesis indicate that carcinomatous components play an important role in the malignant behavior of uterine carcinosarcoma.
Yoshida Y; Kurokawa T; Fukuno N; Nishikawa Y; Kamitani N; Kotsuji F
Hum Pathol; 2000 Dec; 31(12):1448-54. PubMed ID: 11150369
[TBL] [Abstract][Full Text] [Related]
7. [Lymphatic metastasis and VEGF-C expression in ovarian epithelial tumors].
Ding MX; Li JC; Tang XH
Shi Yan Sheng Wu Xue Bao; 2003 Dec; 36(6):445-52. PubMed ID: 14724935
[TBL] [Abstract][Full Text] [Related]
8. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
9. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
10. Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
Hata K; Fujiwaki R; Nakayama K; Maede Y; Fukumoto M; Miyazaki K
Anticancer Res; 2000; 20(5C):3941-9. PubMed ID: 11268481
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors.
Färkkilä A; Anttonen M; Pociuviene J; Leminen A; Butzow R; Heikinheimo M; Unkila-Kallio L
Eur J Endocrinol; 2011 Jan; 164(1):115-22. PubMed ID: 21041381
[TBL] [Abstract][Full Text] [Related]
13. Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis.
Schoell WM; Pieber D; Reich O; Lahousen M; Janicek M; Guecer F; Winter R
Cancer; 1997 Dec; 80(12):2257-62. PubMed ID: 9404702
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of ovarian carcinosarcomas: a single institution experience.
Zorzou MP; Markaki S; Rodolakis A; Kastritis E; Bozas G; Dimopoulos MA; Papadimitriou CA
Gynecol Oncol; 2005 Jan; 96(1):136-42. PubMed ID: 15589592
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vascular endothelial growth factors A, C and D as indicators of lymphangiogenesis and angiogenesis in invasive and non-invasive urothelial carcinoma bladder.
Khadim MT; Ahmed SA; Khan FA; Ikram A; Shaikh SY
J Pak Med Assoc; 2015 Aug; 65(8):851-6. PubMed ID: 26228330
[TBL] [Abstract][Full Text] [Related]
16. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
18. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of VEGF ligands and receptors in prostate cancer.
Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
[TBL] [Abstract][Full Text] [Related]
20. Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.
Hata K; Nakayama K; Fujiwaki R; Katabuchi H; Okamura H; Miyazaki K
Gynecol Oncol; 2004 Apr; 93(1):215-22. PubMed ID: 15047239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
